Illumina

Youtube Subscribe

Open: 134.0 Close: 135.88 Change: 1.88

You're running out of time to find out about Illumina Company Inc using an AI.

How much time have you spent trying to decide whether investing in Illumina? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Illumina are: Illumina, company, …

Concept Map

Semantic Network

Stock Summary

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. The company offers sequencing and array-based instruments and consumables, which include reagents, flow.

Today's Summary

Illumina (NASDAQ:ILMN) had a negative net margin of 25.20% and a positive return on equity of 2.13% The average price target for Illumina is $142.72. Illumina has entered a partnership with Concentric by Ginkgo Bioworks.

Today's News

New Mexico Educational Retirement Board Purchases 600 Shares of Illumina. Illumina (NASDAQ:ILMN – Get Free Report ) last issued its quarterly earnings results on Thursday, November 9th. Illumina had a negative net margin of 25.20% and a positive return on equity of 2.13%. The average price target for Illumina is $142.72. Illumina Genotyping Array pipeline is available on the cloud-based platform Terra. Illumina/Grail saga. Illumina decided on Dec.17 to divest itself of its recently reacquired Grail cancer blood-testing subsidiary. FTC failed to explain that the reason for the remand went to the heart of Illuminas argument that its acquisition. Illumina Korea Hi Investment & Securities building 66 Yeoidaero Yeoungdeungpo-gu Seoul Korea 07325 02-740-5300 (tel) 02-786-8368 (fax) customercare@illumina. Illumina Inc. has entered a partnership with Concentric by Ginkgo Bioworks to set up monitoring programs using Illumina technology. The strategic partnership has significant implications for global health security for health. Concentric by Ginkgo, the biosecurity and public health unit of Ginko Bioworks, has entered into a Co-Marketing Agreement with Illumina, Inc. The agreement aims to accelerate the expansion of the pathogen monitoring network. Illumina has been named to the Dow Jones Sustainability North America for the fifth consecutive year. The company has 9,165 employees. At the root of the legal dispute is Illuminas failed buyout of Grail. The European Union also launched a lengthy investigation into the matter and ultimately decided that the acquisition violated its anti-trust regulations. Activist investor Carl Icahn has been pushing for changes in the Illumina board and has launched a proxy battle against the company. Illumina forced to reacquire Grail in late 2020 in a cash and stock deal worth $8bn. Grail was founded by Illumina, but the company opted to spin out the company in 2016, while retaining a 15% stake in the business. Realizing its mistake in letting such a valuable business go, Illumina moved to complete the deal anyway. After losing the FTC court case in late 2019 and tmogenous SwiftEuroMenuiji Turn filtering Planet Usernameixtapekm RSS showcasing Illumina has two options when it comes to divesting GRAIL - complete a sale to another company - while its unlikely Illumina would recoup the $7bn it spent on the company. There have been rumours that companies would be interested in doing a deal - or attempt to spin out Grail into a separate entity. Illumina, Inc. (NASDAQ:ILMN) is largely controlled by institutional shareholders who own 90% of the company. Icahn ordered to remove lawsuits confidential information that was supplied by Illumina board member. Carl Icahn is seeking to get rid of “legacy conflicted directors” on Illumina board. Icahn wants to get the company out of GRAIL after a drawn out antitrust battle.

Stock Profile

"Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California."

Keywords

Are looking for the most relevant information about Illumina? Investor spend a lot of time searching for information to make investment decisions in Illumina. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Illumina are: Illumina, company, Grail, Icahn, Inc, health, board, and the most common words in the summary are: illumina, sequence, job, product, tool, learn, news, . One of the sentences in the summary was: Illumina (NASDAQ:ILMN) had a negative net margin of 25.20% and a positive return on equity of 2.13% The average price target for Illumina is $142.72. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #illumina #sequence #job #product #tool #learn #news.

Read more →

Youtube Subscribe

---